Sionna Therapeutics’ IPO: A strategic shift in the cystic fibrosis market
Sionna Therapeutics recently secured an initial public offering (IPO) of $191m on the Nasdaq stock exchange, signalling ...
Sionna Therapeutics to Present at the 45th Annual TD Cowen Health Care Conference
Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the ...
pharmaphorum4d
Trial of Boehringer's cystic fibrosis gene therapy imminent
An inhaled gene therapy for cystic fibrosis developed by Boehringer Ingelheim is due to start clinical testing shortly, ...
PharmiWeb5d
Cystic Fibrosis Market: Trends, Insights, and Growth Projections 2025-2035
The global Cystic Fibrosis Market is valued at $10.4 billion in 2023 and is projected to reach $55.4 billion by 2032, ...
Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled gene therapy for people with cystic fibrosis
Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) 1 and OXB, 1 today announce the start of LENTICLAIR TM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, ...
The Hamilton Spectator5d
Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled gene therapy for people with cystic fibrosis
The trial specifically focuses on adults with CF who genetically cannot benefit from cystic fibrosis transmembrane conductance regulator (CFTR) modulators.1 CF is a hereditary, lifelong disease ...
pharmaphorum3d
Boehringer joins UK academics in battle against cystic fibrosis
to introduce a healthy copy of the cystic fibrosis transmembrane conductance regulator (CFTR) gene into the cells of the lung. This method has already demonstrated high gene transfer efficiency ...
manilatimes5d
Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled gene therapy for people with cystic fibrosis
Dr. Frank Mathias, Chief Executive Officer of OXB, said, "We are delighted that Boehringer Ingelheim is using OXB's proprietary lentiviral vector manufacturing technology, to produce lentiviral vector ...
BioWorld5d
Trial begins for inhaled gene therapy for cystic fibrosis
The longstanding ambition of developing an inhaled gene therapy for cystic fibrosis has taken a step forward, with the start of a phase I/II trial of a product using a novel pseudotyped viral vector ...